Tri-ethylene glycol modified class B and class C CpG conjugated gold nanoparticles for the treatment of lymphoma

Adam Yuh Lin*, Jonathan Scott Rink, Reem Karmali, Jiahui Xu, Masha Kocherginsky, Colby Shad Thaxton, Leo I. Gordon

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

CpG oligodeoxynucleotides (CpGs) can induce an anti-tumor immune response, but also uniquely cause direct lymphoma cytotoxicity. To improve the delivery and efficacy of CpGs, we utilized a tri-ethylene modified CpG conjugated gold nanoparticle (tmCpG NP) platform that is compatible with both class B and class C CpGs, to treat various types of lymphoma, including diffuse large B cell lymphoma, high-grade lymphoma, Burkitt's lymphoma, and mantle cell lymphoma. Both classes of tmCpG NPs reduced viability of human and murine lymphoma cells via apoptosis compared with free CpGs, while having no toxic effects on dendritic cells. TmCpG NPs increased CD19, CD20, and OX40 expression on the lymphoma cells. Overall, we introduced a stable tmCpG NP design that has significant anti-lymphoma effects.

Original languageEnglish (US)
Article number102290
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume30
DOIs
StatePublished - Nov 2020

Keywords

  • Apoptosis
  • CpG oligodeoxynucleotides
  • Lymphoma therapy
  • Nanoparticles

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Molecular Medicine
  • Biomedical Engineering
  • Materials Science(all)
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Tri-ethylene glycol modified class B and class C CpG conjugated gold nanoparticles for the treatment of lymphoma'. Together they form a unique fingerprint.

Cite this